1. Bosaeus I, Daneryd P, Svanberg E et al. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 2001; 93(3): 380–383.
2. Bing C, Brown M, King P et al. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 2000; 60(9): 2405–2410.
3. Norton J, Peter J. Nutritional supportive care in principles and practices of pediatric oncology. Philadelphia, PA: Lippincott and Co 1989.
4. Trayhurn P, Bing C. Appetite and energy balance signals from adipocytes. Philos Trans R Soc Lond B Biol Sci 2006; 361(1471): 1237–1249.
5. Bing C, Russell S, Becket E et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br J Cancer 2006; 95(8): 1028–1037.
6. Kim YH, Choi BH, Cheon HG et al. B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation. Exp Mol Med 2009; 41(3): 208–216.
7. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404(6781): 995–999.
8. Huard B, Schneider P, Mauri D et al. T cell costimulation by the TNF ligand BAFF. J Immunol 2001; 167(11): 6225–6231.
9. Ng LG, Sutherland AP, Newton R et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173(2): 807–817.
10. Hamada M, Abe M, Miyake T et al. B cell-activating factor controls the production of adipokines and induces insulin resistance. Obesity (Silver Spring) 2011; 19(10): 1915–1922.
11. Yehudai D, Snir A, Peri R et al. B Cell-Activating Factor Enhances Interleukin-6 and Interleukin-10 Production by ODN-Activated Human B Cells. Scand J Immunol 2012; 76(4): 371–377.
12. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89(2): 381–410.
13. Strassmann G, Fong M, Kenney JS et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89(5): 1681–1684.
14. Fujiki F, Mukaida N, Hirose K et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 1997; 57(1): 94–99.
15. Couluris M, Mayer JL, Freyer DR et al. The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. J Pediatr Hematol Oncol 2008; 30(11): 791–797.
16. Alexaki VI, Notas G, Pelekanou V et al. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. J Immunol 2009; 183(9): 5948–5956.
17. Legaspi A, Jeevanandam M, Starnes HF Jr et al. Whole body lipid and energy metabolism in the cancer patient. Metabolism 1987; 36(10): 958–963.
18. Agustsson T, Ryden M, Hoffstedt J et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007; 67(11): 5531–5537.
19. Zonca M, Mancheno-Corvo P, DelaRosa O et al. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase. Tissue Eng Part A 2012; 18(7–8): 852–859.
20. Jin R, Kaneko H, Suzuki H et al. Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency. Int J Mol Med 2008; 21(2): 233–238.
21. Kohno T, Daa T, Otani H et al. Aberrant expression of BAFF receptor, a member of the tumor necrosis factor receptor family, in malignant cells of nonhematopoietic origins. Genes Cells 2008; 13(10): 1061–1073.